GraphPad Software Acquires SnapGene to Expand Biotechnology Research Software Portfolio

On August 13, 2019, VCBeat (WeChat ID: vcbeat) learned from foreign media reports that software technology company GraphPad Software announced the acquisition of biotechnology company SnapGene; specific transaction details have not been disclosed.

Upon completion of this acquisition, GraphPad Software will further advance the development of the biotechnology sector and provide products, services, and technical support to the global scientific community.

It is reported that SnapGene is the second bioinformatics technology company acquired by GraphPad Software this year.

SnapGene was founded in 2012 by Dr. Benjamin Glick, a professor at the University of Chicago, with a commitment to meeting the research needs of biotechnologists. The company developed SnapGene software for biological researchers, and its users include major research institutions and most biotechnology companies across 65 countries worldwide.

SnapGene software provides a simple and effective way to help researchers plan, document, and share their molecular biology research. SnapGene has also developed innovative DNA cloning technologies to enhance research efficiency in the field of DNA.

Benjamin Glick, Founder and Chief Scientist of SnapGene, stated, “We aim to collaborate with GraphPad Software to accelerate scientific research within the global scientific community. After gaining a deep understanding of the GraphPad Software team, we discovered that we share a common mission. SnapGene is proud to become part of this organization and to advance alongside other industry-leading partners.”

GraphPad Software is a leading software technology company dedicated to supporting scientists at every step of the research and development process. The company serves over one million scientist users worldwide, who leverage GraphPad Software’s products to accelerate the progress of their scientific experiments. GraphPad Software’s product portfolio also includes GraphPad Prism, Geneious DNA data analysis solutions, Geneious Prime, and Geneious Biologics.

Thomas Swalla, CEO of GraphPad Software, stated, “We are delighted to welcome SnapGene. The company is dedicated to advancing scientific research for biotechnology and pharmaceutical firms and has made a significant impact on the life sciences industry. We look forward to leveraging this technology to assist more scientists and further serve the global scientific community.”

Thomas Swalla added, “SnapGene is an insightful biotechnology company that delivers an exceptional user experience and high-quality educational content. We believe the combination of these attributes will help GraphPad Software solidify its leading position in the global scientific research community.”

(Compiled by Hu Yifan)